Crizotinib versus platinum‐based double‐agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase‐positive lung adenocarcinoma

@inproceedings{Zhang2016CrizotinibVP,
  title={Crizotinib versus platinum‐based double‐agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase‐positive lung adenocarcinoma},
  author={Quan Zhang and Na Qin and Jinghui Wang and Jialin Lv and Xinjie Yang and Xi Li and Jingying Nong and Hui Zhang and Xinyong Zhang and Yuhua Wu and Shucai Zhang},
  booktitle={Thoracic cancer},
  year={2016}
}
BACKGROUND To explore the efficacy and safety of crizotinib versus platinum-based double agent chemotherapy as the first-line treatment in patients with advanced anaplastic lymphoma kinase (ALK)-positive lung adenocarcinoma. METHOD We retrospectively analyzed data from 19 patients with advanced ALK-positive lung adenocarcinoma who had received no previous systemic treatment for advanced disease. Seven patients received oral crizotinib at a dose of 250 mg twice daily; 12 patients were… CONTINUE READING
2 Citations
16 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 16 references

[ China EGFR gene sensitivity mutation and Chinese guidelines on diagnosis and treatment of ALK gene - positive non - small - cell lung cancer ( 2014 edition ) . ]

  • DR Camidge, YJ Bang, EL Kwak
  • Chin J Oncol
  • 2014

Clinical significance of EML 4 - ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non - small cell lung cancer

  • AJ Weickhardt, DL Aisner, WA Franklin, M Varella-Garcia, RC Doebele, DR Camidge
  • PLoS ONE
  • 2013

Similar Papers

Loading similar papers…